POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.
High Impact

The BRAIN Act (Bolstering Research And Innovation Now Act)

Original title: BRAIN Act

Last action · April 8, 2025: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Sponsors: Richard Blumenthal and 14 others

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

What This Bill Would Do

The BRAIN Act proposes new federal initiatives to accelerate research into brain tumor treatments, improve patient access to clinical trials, and increase public awareness of cancer testing. It mandates transparency for NIH-funded brain tumor tissue collections and authorizes $50 million annually for research.

Why it matters

This bill would authorize $50 million in annual federal funding from 2026 through 2030 for research and establish new reporting requirements for researchers holding NIH-funded brain tumor tissue samples.

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

Brain tumor patients and families

Patients may see changes in clinical trial access, care monitoring programs, and the development of new immunotherapy treatments.

Directly affected

Medical researchers and institutions

Researchers receiving NIH funding must comply with new reporting requirements for biospecimen collections and may apply for new competitive research grants.

Directly affected

National Institutes of Health

The agency is tasked with establishing new research networks, public websites for biospecimen tracking, and oversight mechanisms for compliance.

Key Facts

  • Authorizes $50 million in annual appropriations for fiscal years 2026 through 2030 for the Glioblastoma Therapeutics Network.
  • Requires individuals or entities holding NIH-funded brain tumor biospecimens to report collection details to the NIH Director.
  • Existing biospecimen collections must be reported within 180 days of enactment; new collections must be reported within 60 days.
  • Establishes an oversight mechanism for biospecimen reporting, including the potential to withhold funding for repeated or egregious violations.
Show all 9 facts
  • Directs the NIH to create a searchable public website detailing the existence and location of NIH-funded brain tumor biospecimen collections.
  • Mandates the creation of a multi-institutional research program for brain tumor cellular immunotherapy, including CAR-T treatments for adults and children.
  • Directs the FDA to issue guidance aimed at ensuring brain tumor patient access to clinical trials.
  • Requires a national public awareness campaign regarding cancer clinical trials and biomarker testing.
  • Establishes pilot programs to study and evaluate monitoring and care approaches for brain tumor survivors.

Frequently Asked Questions

What is a 'covered biospecimen collection' under this bill?
It refers to brain tumor tissue, cerebral spinal fluid, or other specimens collected or acquired using funding from the National Institutes of Health.
How will the bill affect researchers who hold brain tumor samples?
Researchers holding NIH-funded samples must report them to the NIH Director. Failure to comply with these reporting requirements could result in the withholding of NIH funding.
What is the Glioblastoma Therapeutics Network?
A research program to be established by the NIH to improve treatment by evaluating therapeutic agents from pre-clinical development through early-phase human clinical trials.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently in committee. The next step in the legislative lifecycle is Floor Vote.

Procedural history

2 actions
  1. Apr 8, 2025SenateCommittee
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  2. Apr 8, 2025SenateIntroduced
    Introduced in Senate

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

The Cleveland Clinic Foundation

on behalf of Cleveland Clinic Foundation

$130,000

2026

HEALTH ISSUESMEDICARE/MEDICAID

“Quantum computing Immigration Issues National Institute of Health CHILDReN Act EARLY Minds Act Interoperability Issues Brain Health 340B Graduate Medical Education Workforce Issues Payer Accountability Organ Transplant Legislation Healthy Competition Act Price Transparency ”

Senate LDAMatched on title words onlyView filing on LDA.gov →

HEALTH AND MEDICINE COUNSEL, LLC

on behalf of VOICES AGAINST BRAIN CANCER

Senate LDAMatched on title words onlyView filing on LDA.gov →

Cleveland Clinic Foundation

$240,000

2024

HEALTH ISSUESMEDICARE/MEDICAID

“Telehealth Artificial intelligence Quantum legislation National Institutes of Health Reform Medical Nutrition Therapy Act The REDUCE Act Amputation Reduction and Compassion Act Affordable housing School-based health Food insecurity Breast cancer innovation Traumatic Brain Injury Technology Graduate Medical Education Reform Wage index Tax Exempt Status ”

Senate LDAMatched on title words onlyView filing on LDA.gov →

Cleveland Clinic Foundation

on behalf of The Cleveland Clinic Foundation

$130,000

2022

HEALTH ISSUESMEDICARE/MEDICAID

“SANE Act Telehealth (H.R.4040) Hospital-at-Home Food insecurity NQF Funding Brain Health NIH Reform No Surprise Act implementation ”

Senate LDAMatched on title words onlyView filing on LDA.gov →

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Increased Oversight of NIH-funded Research

The bill introduces a formal oversight mechanism that explicitly links the withholding of federal funding to non-compliance with biospecimen reporting requirements.

Connected Entities

John Barrasso, Jack Reed, Food and Drug Administration and 3 more
PersonJohn Barrasso“U.S. Senator who co-sponsored the bill.”Map →
PersonJack Reed“U.S. Senator who co-sponsored the bill.”Map →
OrganizationFood and Drug Administration“Agency tasked with providing guidance on clinical trial access.”Map →
OrganizationNational Institutes of Health“Primary agency responsible for managing research programs and biospecimen report”Map →
PersonMike Rounds“U.S. Senator who co-sponsored the bill.”Map →
PersonRichard Blumenthal“U.S. Senator who introduced the bill.”Map →

Sources

Open source document

www.congress.gov

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy10
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz20
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record